Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Center Study to Evaluate the Effect of Riluzole Oral Soluble Film on Swallowing Safety in Individuals With Amyotrophic Lateral Sclerosis (ALS)

Trial Profile

A Single Center Study to Evaluate the Effect of Riluzole Oral Soluble Film on Swallowing Safety in Individuals With Amyotrophic Lateral Sclerosis (ALS)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2019

At a glance

  • Drugs Riluzole (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions
  • Acronyms ROSF
  • Sponsors Aquestive Therapeutics
  • Most Recent Events

    • 06 Nov 2018 Status changed from recruiting to discontinued, as reported in the Aquestive Therapeutics media release.
    • 06 Nov 2018 According to an Aquestive Therapeutics media release, the company reached an agreement with the FDA to end the swallowing study, sooner than previously planned based on an analysis of the study's interim data. Topline results are expected to be reported in late 2018 and an NDA submission is expected in the first quarter of 2019.
    • 27 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top